[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thymoma-and-thymic-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thymoma-and-thymic-carcinoma":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100628567","phase-2-6-vs-3-cycles-of-neoadjuvant-chemotherapy-for-potentially-resectable-locally-advanced-thymic-epithelial-tumors-100628567",false,"NCT07463313","6 vs 3 Cycles of Neoadjuvant Chemotherapy for Potentially Resectable Locally Advanced Thymic Epithelial Tumors","A Randomized Controlled Trial of 6 Versus 3 Cycles of Neoadjuvant Chemotherapy on Event-Free Survival in Patients With Potentially Resectable Locally Advanced Thymic Epithelial Tumors","Inclusion Criteria:\n\n* Histologically or cytologically confirmed thymic epithelial tumor (thymoma or thymic carcinoma)\n* Locally advanced, potentially resectable disease (Masaoka-Koga stage III or IVA), as evaluated by a multidisciplinary team (MDT) including thoracic surgery and thoracic oncology\n* Age 18 to 65 years\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Adequate bone marrow function: absolute neutrophil count (ANC) ≥1.5×10⁹\u002FL, platelet count ≥100×10⁹\u002FL, hemoglobin ≥90 g\u002FL\n* Adequate liver function: total bilirubin ≤1.5× upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN\n* Adequate renal function: creatinine clearance ≥50 mL\u002Fmin (Cockcroft-Gault formula)\n* No prior systemic anticancer therapy for thymic epithelial tumor\n* At least one measurable lesion per RECIST v1.1\n* Willing to accept randomization and able to comply with study procedures\n* Written informed consent obtained prior to any study-related procedures\n\nExclusion Criteria:\n\n* Prior chemotherapy, targeted therapy, or immunotherapy for thymic epithelial tumor\n* Prior thoracic radiation therapy\n* Active autoimmune disease requiring systemic treatment within the past 2 years\n* Known hypersensitivity or contraindication to study drugs (cisplatin, epirubicin, etoposide, ifosfamide, or any component of these formulations)\n* Severe cardiac dysfunction: New York Heart Association (NYHA) class III or IV heart failure, or left ventricular ejection fraction (LVEF) \\\u003C50%\n* Active hepatitis B (HBsAg positive with HBV DNA ≥2000 IU\u002FmL), active hepatitis C, or known HIV infection\n* Pregnancy or lactation; women of childbearing potential unwilling to use adequate contraception\n* Other malignancy within 5 years prior to enrollment, except for adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix\n* Uncontrolled active infection requiring systemic therapy\n* Any condition that, in the investigator's judgment, would preclude safe participation in the study","ALL","18 Years","65 Years",{"count":20,"type":21},116,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE2","PHASE3","This randomized controlled trial compares 6 versus 3 cycles of neoadjuvant chemotherapy in patients with potentially resectable locally advanced thymic epithelial tumors (TETs, WHO type AB\u002FB\u002FC, AJCC TNM stage IIIA-IVA). Patients are randomized 1:1 to receive either 6 or 3 cycles of chemotherapy (cisplatin + doxorubicin + cyclophosphamide for type B; nab-paclitaxel + carboplatin for type C thymoma\u002Fthymic carcinoma) every 3 weeks, followed by surgical resection when feasible. The primary endpoint is event-free survival (EFS). The study aims to determine whether extended neoadjuvant chemotherapy improves surgical outcomes and long-term survival in this rare malignancy.",[28],"Thymoma and Thymic Carcinoma",[30,31,32,33,34],"Neoadjuvant Chemotherapy","Thymic Epithelial Tumor","Thymic Carcinoma","Event-Free Survival","Mediastinal Tumor","NOT_YET_RECRUITING","2026-03-06",{"date":38,"type":39},"2026-03-11","ACTUAL",{"date":41,"type":21},"2026-03",{"date":43,"type":21},"2032-03",{"name":45,"class":46},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":47},"100569270","hypofractionated-radiotherapy-for-thymic-epithelial-tumors-100569270","NCT06692062","Hypofractionated Radiotherapy for Thymic Epithelial Tumors","A Prospective Study of Hypofractionated Radiotherapy for Thymic Epithelial Tumors","Inclusion Criteria:\n\n1. Patients must provide written informed consent.\n2. 18 years old ≤ age \\\u003C75 years old.\n3. Thymoma confirmed by pathology: type A, type AB, type B1, type B2, type B3. Thymic carcinoma. Patients with previous thymectomy were required to have complete surgical related data.\n4. Masaoka⁃Koga ⁃ stage Ⅰ-Ⅲ\n5. ECOG performance status 0-2.\n6. Expected survival time \\> 1 year.\n7. Participants of childbearing age must agree to use effective contraception during the trial; In women of childbearing age, a serum or urine pregnancy test must be negative.\n8. Patients who are not lactating.\n9. Sufficient bone marrow reserve and good function of important organs.\n\nExclusion Criteria:\n\n1. patients with prior thoracic radiotherapy;\n2. diseases not suitable for radiotherapy, such as recent myocardial infarction, active congestive heart failure;\n3. Uncontrolled infectious disease or other serious medical or mental illness that may interfere with care\n4. Patients with other malignant tumors that are not under stable control;\n5. Known history of mental illness, substance abuse, alcohol or drug abuse.\n6. Other conditions deemed unsuitable for enrollment by the attending physician.","75 Years",{"count":57,"type":21},100,[59],"NA","The goal of this clinical trial is to learn if hypofractionated radiotherapy works to shorten the treatment time without increasing the side effects in patients of thymic epithelial tumors. The main questions it aims to answer are:\n\n* Does Hypofractionated radiotherapy provide better results?\n* Can hypofractionated radiotherapy reduce toxic and side effects compared with conventional radiotherapy? Researchers will compare the efficacy and safety of hypofractionated radiotherapy after thymic tumor surgery.\n\nParticipants will:\n\n* Receive hypofractionated radiotherapy or conventional radiotherapy\n* Visit the hospital regularly once every 12 weeks for checkups and tests",[28,62,63,31],"Thymoma","Thymic Cancer",[65,66,67],"thymoma","hypofractionated radiotherapy","thymic carcinoma","RECRUITING","2024-11-15",{"date":71,"type":39},"2024-11-18",{"date":73,"type":39},"2024-10-01",{"date":75,"type":21},"2027-11-01",{"name":77,"class":46},"Rongrong Zhou",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":89,"conditions":90,"keywords":91,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":47},"100539292","artificial-intelligence-prediction-tool-in-thymic-epithelial-tumors-100539292","NCT06301945","Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors","Artificial Intelligence for Histopathological Classification and Recurrence Prediction of Thymic Epithelial Tumors","INTHYM","Inclusion Criteria:\n\nParticipants with specific diagnoses are eligible for inclusion in the study. The eligible diagnoses include various subtypes of thymoma and thymic carcinoma, specifically:\n\n* Thymoma A\n* Thymoma AB\n* Thymoma B1\n* Thymoma B2\n* Thymoma B3\n* Thymic Carcinoma\n\nInclusion is based on a consensus diagnosis with a level of agreement less than 70%. This criterion is applied during the training phase of the model.\n\nRecurrence Criteria:\n\nParticipants with a documented recurrence outcome within a 5-year period are considered eligible for this aspect of the study. This criterion is primarily applied during the validation phase.",{"count":87,"type":21},1020,"OBSERVATIONAL","Thymic epithelial tumors are rare neoplasms in the anterior mediastinum. The cornerstone of the treatment is surgical resection. Administration of postoperative radiotherapy is usually indicated in patients with more extensive local disease, incomplete resection and\u002For more aggressive subtypes, defined by the WHO histopathological classification.\n\nIn this classification thymoma types A, AB, B1, B2, B3, and thymic carcinoma are distinguished. Studies have shown large discordances between pathologists in subtyping these tumors. Moreover, the WHO classification alone does not accurately predict the risk of recurrence, as within subtypes patients have divergent prognoses.\n\nThe investigators will develop AI models using digital pathology and relevant clinical variables to improve the accuracy of histopathological classification of thymic epithelial tumors, and to better predict the risk of recurrence.\n\nIn this multicentric and international project three existing databases will be used from Rotterdam, Maastricht and Lyon. For all models one database will be used to build AI models, and the other two for external validation.\n\nThe ultimate goal of this project is to develop AI models that support the pathologist in correctly subtyping thymic epithelial tumors, in order to prevent patients from under- or overtreatment with adjuvant radiotherapy.",[31,32,62,28],[92,93],"Artificial Intelligence","Digital pathology","2024-03-26",{"date":96,"type":39},"2024-03-27",{"date":98,"type":39},"2023-08-01",{"date":100,"type":21},"2027-08-01",{"name":102,"class":46},"Erasmus Medical Center"]